

AGENDA

**Uniform Formulary Beneficiary Advisory Panel (BAP)
10 January 2019 @ 9:00 AM**

**Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting (BAP members report no later than 8:45 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF).

The P&T Committee made recommendations for the following drugs/drug classes during the November 2018 meeting:

- **Drug Class Reviews**
 - *Gastrointestinal-2 Agents – Chronic Idiopathic Constipation (CIC) and Constipation-Predominant Irritable Bowel Syndrome (IBS-C) and Gastrointestinal-2 Agents – Miscellaneous Subclasses*
 - *Neurological Agents Miscellaneous – Movement Disorders Subclass*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *adapalene 0.1% topical solution (external pad/swab) (Plixda) – Topical Acne Agent*
 - *adapalene 0.1% topical solution – Topical Acne Agent*
 - *amikacin liposome inhaled suspension (Arikayce) – Aminoglycoside Antibiotic for Mycobacterium Avium Complex (MAC)*
 - *butalbital 50 mg and acetaminophen 300 mg capsules – Analgesics and Combinations*
 - *cannabidiol oral solution (Epidiolex) – Anticonvulsants-Antimania Agent for Lennox-Gastaut Syndrome or Dravet Syndrome*
 - *dacomitinib (Vizimpro) – Oncologic Agent for Non-Small Cell Lung Cancer (NSCLC)*
 - *darunavir/cobicistat/emtricitabine/tenofovir alafenamide (TAF) (Symtuza) – Combination Antiretroviral for HIV*

- *darunavir/lamivudine/tenofovir disoproxil fumarate (TDF) (Delstrigo) – Combination Antiretroviral for HIV*
- *doravirine (Pifeltro) – Antiretroviral for HIV*
- *doxycycline monohydrate extended release (ER) capsules (Okebo) – Oral Tetracycline Agent*
- *duvelisib (Copiktra) – Oncologic Agent for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)*
- *elagolix (Orilissa) – Luteinizing Hormone-Releasing Hormone (LHRH) Agonists-Antagonists for Endometriosis*
- *filgrastim-aafi injection (Nivestym) – Hematologic Agent: White Blood Cell Stimulant*
- *fremanezumab-vfrm injection (Ajovy) – Migraine Agent (calcitonin gene-related peptide [CGRP]) for Migraine Headache Prophylaxis*
- *galcanezumab-gnlm injection (Emgality) – Migraine Agent (CGRP) for Migraine Headache Prophylaxis*
- *glycopyrronium 2.4% topical cloth (Qbrexza) – Antiperspirant for Primary Axillary Hyperhidrosis*
- *ivosidenib (Tibsovo) – Oncologic Agent for Acute Myelogenous Leukemia (AML)*
- *lanadelumab injection (Takhzyro) – Corticosteroid-Immune Modulator for Hereditary Angioedema (HAE) Prophylaxis*
- *lidocaine 1.8% topical patch (ZTlido) – Topical Pain Agent*
- *lumacaftor/ivacaftor granules (Orkambi) – Cystic Fibrosis Agent*
- *lusutrombopag (Mulpleta) – Hematologic Agent: Platelets for Thrombocytopenia in Chronic Liver Disease*
- *metoprolol ER capsules (Kaspargo Sprinkle) – Beta-Blocker*
- *migalastat (Galafold) – Miscellaneous Metabolic Agent for Fabry Disease*
- *minocycline ER tablets (Minolira) – Oral Tetracycline Agent*
- *ozenoxacin 1% cream (Xepi) – Quinolone Antibiotic for Impetigo*
- *PEG33350/Na ascorbate/NaSO4/ascorbic acid/NaCl/KCl powder packets (Plenvu) – Laxatives-Cathartics-Stool Softener for Bowel Prep*
- *pegfilgrastim-jmdb injection (Fulphila) – Hematologic Agent: White Blood Cell Stimulant*
- *PEGylated Factor VIII (Jivi) – Antihemophilic Factor*
- *sodium zirconium cyclosilicate packet for oral suspension (Lokelma) – Binders Chelators Overdose Agents Hyperkalemia*
- *tildrakizumab-asmn injection (Ilumya) – Targeted Immunomodulatory Biologic (TIB) for Plaque Psoriasis*

- *tretinoin 0.05% topical lotion (Altreno) – Topical Acne Agent*
- **Utilization Management Issues**
 - **Prior Authorization Criteria—Updated Criteria**
 - *Basal Insulins: Insulin degludec (Tresiba)*
 - *Corticosteroids – Immune Modulators – Atopic Dermatitis Subclass: dupilumab (Dupixent) injection*
 - *Anti-Gout Drugs: Febuxostat (Uloric)*
 - *Antipsychotic Agents – Atypical: pimavanserin (Nuplazid)*
 - *Antihemophilic Factors: emicizumab-kxwh (Hemlibra)*
 - *Targeted Immunomodulatory Biologics (TIBs)*
 - **Prior Authorization Criteria—New Criteria**
 - *Pain Agents—Non-steroidal Anti-inflammatory Drugs (NSAIDs): diclofenac potassium liquid-filled capsules (Zipsor), diclofenac submicronized (Zorvolex), indomethacin submicronized (Tivorbex), naproxen CR (controlled-release) (Naprelan/generics), meloxicam submicronized (Vivlodex)*
 - *Skeletal Muscle Relaxants and Combinations: chlorzoxazone 250 mg tablets*
 - *Oncological Agents for unresectable or metastatic melanoma: cobimetinib (Cotellic)*
 - *Antiinfectives: Miscellaneous: crotamiton 10% lotion (Eurax and Crotan)*
- **Re-evaluation of NF Generics—ADHD/Wakefulness: Stimulants Subclass**
- **Section 703, National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2008**
- **Informational Items**
 - ***Removal of Brand over Generic Authority and Brand over Generic PA Criteria Authorization for Sildenafil Tablets (Viagra)***
 - ***Drugs Losing Rx Status and Moving to OTC Status (Vitamin B Replacement Products, Iron Replacement Products, and Urinary pH Modifiers)***
 - ***TRICARE Mail Order Auto Refill Requirements for Self-Monitoring Blood Glucose Systems (SMBGS) Test Strips and Lancets***
- **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.